NASDAQ:LPTX - Leap Therapeutics Stock Price, Forecast & News

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Leap Therapeutics Inc (NASDAQ:LPTX) announced its earnings results on Thursday, November, 14th. The company reported ($0.33) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.33). View Leap Therapeutics' Earnings History.

Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Leap Therapeutics.

3 analysts have issued twelve-month price objectives for Leap Therapeutics' shares. Their forecasts range from $2.50 to $6.00. On average, they expect Leap Therapeutics' stock price to reach $3.92 in the next year. This suggests a possible upside of 36.1% from the stock's current price. View Analyst Price Targets for Leap Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics.

Media stories about LPTX stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Leap Therapeutics earned a news impact score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Leap Therapeutics.

Leap Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,160,000 shares, an increase of 23.1% from the January 15th total of 942,100 shares. Based on an average trading volume of 656,900 shares, the short-interest ratio is presently 1.8 days. Currently, 8.0% of the shares of the company are sold short. View Leap Therapeutics' Current Options Chain.

Some companies that are related to Leap Therapeutics include Nature's Sunshine Products (NATR), Fortress Biotech (FBIO), Cerecor (CERC), TAIWAN LIPOSOME/S (TLC), Chiasma (CHMA), Athersys (ATHX), GlycoMimetics (GLYC), Ovid Therapeutics (OVID), Kezar Life Sciences (KZR), Strongbridge Biopharma (SBBP), Neptune Wellness Solutions (NEPT), Spero Therapeutics (SPRO), NuCana (NCNA), Avenue Therapeutics (ATXI) and Akorn (AKRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Sorrento Therapeutics (SRNE), Verastem (VSTM), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Nabriva Therapeutics (NBRV) and Pieris Pharmaceuticals (PIRS).

Leap Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (2.73%). View Institutional Ownership Trends for Leap Therapeutics.

LPTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. View Insider Buying and Selling for Leap Therapeutics.

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LPTX stock can currently be purchased for approximately $2.88.

Leap Therapeutics has a market capitalization of $69.60 million. The company earns $-23,140,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe.View Additional Information About Leap Therapeutics.

The official website for Leap Therapeutics is http://www.leaptx.com/.

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.